Changing the pathophysiology of solid tumours: The potential of TNF and other vasoactive agents

International Journal of Hyperthermia

Volumn 22, Issue 3, 2006, Pages 241-246

  ten Hagen, Timo L M ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Perfusion; Regional therapy; Solid tumour; TNF; Tumour pathophysiology; Vasoactive drugs

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; HISTAMINE; INTERLEUKIN 2; LIPOSOME; MELPHALAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VASOACTIVE AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HUMAN; IC 50; LIMB PERFUSION; LIVER CANCER; MELANOMA; METHODOLOGY; PATHOPHYSIOLOGY; SOLID TUMOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; MICROCIRCULATION; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTOR AGENTS;

EID: 33745071850     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730600738616     Document Type: Conference Paper

References (27)

1. Jain, RK. (1989) Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies J Natl Cancer Inst, 81, pp. 570-576.
2. Eggermont, AM and de Wilt, JH and ten Hagen, TL. (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies Lancet Oncol, 4, pp. 429-437.
3. Creech, OJ and Krementz, ET and Ryan, RF and Winblad, JN. (1958) Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit Ann Surg, 148, pp. 616-632.
4. Benckhuijsen, C and Kroon, BB and Van Geel, AN and Wieberdink, J. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics Eur J Surg Oncol, 14, pp. 157-163.
5. Klaase, JM and Kroon, BB and Benckhuijsen, C and Van Geel, AN and Albus-Lutter, CE and Wieberdink, J. (1989) Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities Cancer, 64, pp. 616-621.
6. Vrouenraets, BC and Klaase, JM and Nieweg, OE and Kroon, BB. (1998) Toxicity and morbidity of isolated limb perfusion Semin Surg Oncol, 14, pp. 224-231.
7. Rossi, CR and Mocellin, S and Pilati, P and Foletto, M and Nitti, D and Lise, M. (2003) TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: State of the art and future trends J Immunother, 26, pp. 291-300.
8. Klaase, JM and Kroon, BB and Van Geel, AN and Eggermont, AM and Franklin, HR and van Dongen, JA. (1993) A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb Cancer, 71, pp. 2990-2994.
9. Krementz, ET and Carter, RD and Sutherland, CM and Hutton, I. (1977) Chemotherapy of sarcomas of the limbs by regional perfusion Ann Surg, 185, pp. 555-564.
10. Eggermont, AMM and Manusama, ER and ten Hagen, TLM. (1995) Regional application of TNF alpha in the treatment of cancer: A preclinical-clinical interactive program J Inflamm, 47, pp. 104-113.
11. Hagen, TLM and Eggermont, AMM and Lejeune, FJ. (2001) TNF is here to stay-revisited Trends Immunol, 22, pp. 127-129.
12. Olieman, AF and van Ginkel, RJ and Hoekstra, HJ and Mooyaart, EL and Molenaar, WM and Koops, HS. (1997) Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor Ann Surg Oncol, 4, pp. 64-69.
13. de Wilt, JHW and ten Hagen, TLM and de Boeck, G and van Tiel, ST and de Bruijn, EA and Eggermont, AMM. (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br J Cancer, 82, pp. 1000-1003.
14. Vrouenraets, BC and Kroon, BB and van de Merwe, SA and Klaase, JM and Broekmeyer-Reurink, MP and van Slooten, GW and Nieweg, OE and van der Zee, J and van Dongen, JA. (1996) Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: A pilot study Eur Surg Res, 28, pp. 235-244.
15. Klaase, JM and Kroon, BB and van Slooten, GW and van Dongen, JA and van de Merwe, SA and van der, ZJ. (1994) Comparison between the use of whole blood versus a diluted perfusate in regional isolated perfusion by continuous monitoring of transcutaneous oxygen tension: A pilot study J Invest Surg, 7, pp. 249-258.
16. de Wilt, JHW and Manusama, ER and van Tiel, ST and Van Ijken, MGA and ten Hagen, TLM and Eggermont, AMM. (1999) Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats Br J Cancer, 80, pp. 161-166.
17. Ruegg, C and Yilmaz, A and Bieler, G and Bamat, J and Chaubert, P and Lejeune, FJ. (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma Nat Med, 4, pp. 408-414.
18. Brouckaert, P and Takahashi, N and van Tiel, ST and Hostens, J and Eggermont, AM and Seynhaeve, AL and Fiers, W and ten Hagen, TL. (2004) Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics Int J Cancer, 109, pp. 442-448.
19. ten Hagen, TLM and Van Der Veen, AH and Nooijen, PTGA and van Tiel, ST and Seynhaeve, ALB and Eggermont, AMM. (2000) Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats Int J Cancer, 87, pp. 829-837.
20. Friedl, J. Turner. E and Alexander, HR, Jr. (2003) Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: Evidence for disruption of vascular integrity via VE-cadherin down-regulation Int J Oncol, 23, pp. 611-616.
21. Brunstein, F and Hoving, S and Seynhaeve, AL and van Tiel, ST and Guetens, G and de Bruijn, EA and Eggermont, AM and ten Hagen, TL. (2004) Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: Preclinical studies J Natl Cancer Inst, 96, pp. 1603-1610.
22. Hoving, S and Brunstein, F and aan de Wiel-Ambagtsheer, G and van Tiel, ST and de Boeck, G and de Bruijn, EA and Eggermont, AM and ten Hagen, TL. (2005) Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats Cancer Res, 65, pp. 4300-4308.
23. Baxter, LT and Jain, RK. (1989) Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection Microvasc Res, 37, pp. 77-104.
24. Kristensen, CA and Nozue, M and Boucher, Y and Jain, RK. (1996) Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts Br J Cancer, 74, pp. 533-536.
25. Willett, CG and Boucher, Y and di Tomaso, E and Duda, DG and Munn, LL and Tong, RT and Chung, DC and Sahani, DV and Kalva, SP and Kozin, SV and Mino, M and Cohen, KS and Scadden, DT and Hartford, AC and Fischman, AJ and Clark, JW and Ryan, DP and Zhu, AX and Blaszkowsky, LS and Chen, HX and Shellito, PC and Lauwers, GY and Jain, RK. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med, 10, pp. 145-147.
26. Gerber, HP and Ferrara, N. (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res, 65, pp. 671-680.
27. Eikenes, L and Tari, M and Tufto, I and Bruland, OS and de Lange, DC. (2005) Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts Br J Cancer, 93, pp. 81-88.